https://www.hcplive.com/view/kingfisher-brolucizumab-noninferiority-aflibercept-dme-treatment
0
0
11/28/23 at 5:01pm
Organization
Hcplive.com
Author
Connor Iapoce
33 words
0
Comments
The phase 3 trial results show brolucizumab had superior anatomic improvements compared to aflibercept, with no clinically meaningful differences in visual outcomes.
You are the first to view
Create an account
or login to join the discussion